Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters.
BACKGROUND
Oxidative stress during hemodialysis is thought to promote the progression of vascular complications in hemodialysis patients. The protective role of vitamin E as a lipophilic antioxidant against oxidative stress has been widely investigated. Here we investigated the effects of a vitamin E-coated regenerated cellulose hollow fiber dialyzer (CL-EE) on oxidative stress compared with a polysulfone hollow fiber (CL-PS).


METHODS
For at least three months before beginning the protocol, 10 nondiabetic (NDM) patients (70.0 +/- 7.5 years; 6 males and 4 females) and 8 diabetic (DM) patients (65.0 +/- 7.4 years; 4 males, 4 females) were dialyzed with CL-PS. After that, we treated all of the patients with CL-EE for six months. Malondialdehyde (MDA), advanced glycation end products (AGEs), and 8-hydroxydeoxyguanosine (8-OHdG) were monitored as biomarkers for oxidative stress at the start and then at one, three, and six months into treatment with CL-EE.


RESULTS
Serum MDA, AGE, and 8-OHdG levels increased after the hemodialysis with CL-PS. The increase of the biomarkers was completely prevented by a single use of CL-EE. Long-term hemodialysis with CL-EE for six months significantly reduced the basal levels of the oxidant markers at one month for AGE and at six months for 8-OHdG in both DM and NDM patients. Serum MDA was reduced in only DM patients at three months. The improvement of the oxidative stress with CL-EE was more prominent in the DM patients.


CONCLUSIONS
Long-term treatment with CL-EE efficiently improves the oxidative stress associated with hemodialysis and potentially reduces dialysis complications due to oxidative stress.
Satoh
M
M
Department of Medicine III, Okayama University Medical School, Okayama, Japan. satoh-minoru@mxl.tiki.ne.jp
Yamasaki
Y
Y
Nagake
Y
Y
Kasahara
J
J
Hashimoto
M
M
Nakanishi
N
N
Makino
H
H
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000368:Aged; D000975:Antioxidants; D002482:Cellulose; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000097:blood; D003928:Diabetic Nephropathies / Q000097:blood / Q000628:therapy; D005260:Female; D016166:Free Radical Scavengers; D017127:Glycation End Products, Advanced / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D007688:Kidneys, Artificial; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress; D011108:Polymers; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D013450:Sulfones; D013997:Time Factors; D014810:Vitamin E
D000975:Antioxidants; D016166:Free Radical Scavengers; D017127:Glycation End Products, Advanced; D011108:Polymers; D013450:Sulfones; D014810:Vitamin E; C017662:polysulfone P 1700; D008315:Malondialdehyde; D000080242:8-Hydroxy-2'-Deoxyguanosine; D002482:Cellulose; D003849:Deoxyguanosine